Commercial Outlook of Pain Markets

• Gain insight into the pain market dynamics that will impact on market shares and sales of currently marketed pain drugs.
• Know your future competition: pipeline analysis and forecasts of key analgesics in late stage development.
• Prepare for the commercial impact of emerging analgesics currently in development in phases II and III.
• Focus resources on the critical success factors for competing successfully in pain markets.

 

What sets this course apart?

The faculty: In Europe, Datamonitor is the only business intelligence company with a team of CNS & Pain market analysts dedicated to analyzing unmet medical need, epidemiological trends, therapeutic algorithms, pipelines, and capable of projecting sales forecasts of current and emerging analgesics on that basis. These seminars offer a unique opportunity to closely interact with Datamonitor’s lead analysts.

The content: Datamonitor shares the best of their research with you in this seminar. You will be exposed to the most valuable information and insights that their analysts have published in reports on pain markets, in a format that fosters interaction and learning.

Who should attend?

Anyone involved in the marketing of current and late stage development pain therapeutics.

Past participants

Market Access Manager	AstraZeneca	Netherlands
Market Research Manager Oncology	Bayer Schering Pharma	Germany
Global Brand Manager	Bayer Schering Pharma	Deutschland
Market Manager Europe	Becton Dickinson	France
Head of Cdept. Customer Group Urologist /Oncologists	Boehringer Ingelheim	Germany
Senior Project Manager - Oncology	Chugai	UK	Testimonial
CSO, VP	Egalet	Denmark
Head of Strategy & Commercial Analysis	GlaxoSmithKline	France
Head of Marketing Intelligence	Janssen-Cilag	UK
New Product Development Director	Johnson & Johnson	USA
International Product Manager	Novo Nordisk	Denmark
Product Manager	Novo Nordisk	Netherlands
Senior Director / Group Leader	Pfizer	USA
Oncology Business Analyst	Roche	UK
Medical Manager	Sanofi-aventis	Belgium	Testimonial
Market Research Specialist	Sanofi-aventis	Belgium
Vice President NPC CNS	UCB	Belgium
Director New Product Commercialization CNS	UCB	Belgium	Testimonial

Programme outline

You are welcome to join us for the welcome coffee at 9:30. The actual programme starts at 10:00 and closing will be no later than 17:00.

The programme consists of a sequence of interactive lectures focusing on specific pain markets. During each presentation, Datamonitor’s lead analysts will share the following data and insights:

• Current market trends and dynamics
• Commercial opportunities and threats
• Lifecycle management strategies
• Pipeline assessment
• Market forecasts, assumptions and events
• Strategic recommendations and conclusions

Q&A sessions at the end of each presentation will be moderated by Dr. Richard Faint, who is very effective in engaging the audience in a discussion with analysts.

09:30 - 10:00	Welcome Coffee
10:00 - 10:15	Introductions
10:15 - 11:00	Introduction to Pain Market Dynamics and Issues
11:00 – 11:45	Short Acting Opioids - Drug delivery reformulations rival Cephalon This presentation will enable delegates to understand the commercial potential of the numerous pipeline short-acting opioid drug delivery reformulations in development, and their impact on Cephalon’s market leading franchise (Actiq, Fentora).
11:45 – 12:00	Coffee Break
12:00 – 12:45	Fibromyalgia - First FDA approval set to give rise to keenly anticipated market The historically misunderstood fibromyalgia market is soon to become a competitive, yet highly lucrative arena. This presentation offers insight into how the future market will take shape, exploring key pipeline agents, product positioning, and strategies for success.
12:45 – 13:30	Lunch
13:30 – 14:15	Osteoarthritis - The COX-2 pipeline collapses  In 2007, the FDA did not approve either Merck’s Arcoxia or Novartis’s Prexige and the COX-2 pipeline has evaporated. This presentation provides a historical overview of the osteoarthritis market, reviews the key late-stage pipeline and explores the future competitive landscape to 2017.
14:15 – 15:00	Migraine - Opportunities will exist in the wake of generic attack The launch of current pipeline drugs are predicted to only periodically offset genericization of the triptans and Topamax over the next 10 years. The presentation explores the most attractive opportunities in the future migraine market as well as the main barriers to entry.
15:00 – 15:15	Coffee break
15:15 – 16:00	Long Acting Opioids -Anti-abuse market set for blockbuster proportions This presentation will enable delegates to understand the commercial potential of anti-abuse technologies in the opioid market, and appreciate the opioid market landscape post-OxyContin patent expiry.
16:00 – 16:45	Neuropathic Pain - Expanding market demonstrates potential Pfizer’s success with Lyrica has boosted interest in the neuropathic pain market and several variant mechanisms of action are currently under investigation vying to offer increased pain control. The presentation reviews the pipeline and assesses the future market landscape.
16:45 – 17:00	Final discussion & Closing remarks

Meet the experts:

Richard Faint, PhD, MBA

• Joined Datamonitor in 2003 and is currently Datamonitor’s Director Disease Analysis, spanning over all therapy markets.
• Successful moderator with several C.E.L.forpharma therapy market seminars since 2006.
• Formerly with Xenova plc, a biopharmaceutical company.
• PhD (University of London) in cell signalling mechanisms; MBA.
  

Ben Greener, BSc

• Joined Datamonitor in 2001 and is currently Datamonitor’s Lead Analyst CNS & Pain business team providing in-depth market analysis and insight.
• Developed and successfully led C.E.L.forpharma’s CNS Market Outlook seminar in 2007.
• BSc in Biological Sciences from the University of Sheffield, UK
  

Terence McManus, PhD

• Dr. Terence McManus is currently a Senior Healthcare Analyst in the CNS team at Datamonitor.
• At Datamonitor, Terence has authored over a dozen industry reports covering all major CNS drug markets.
• Prior to joining Datamonitor in 2006, Terence held the position of Manager of Assay Development and Services at UK based biotechnology company Capsant Neurotechnologies, where he was focused on CNS lead drug validation services.
• Terence received a PhD from The University of Southampton, where the focus of his PhD project was on mechanisms of neurodegeneration.
  

Martin Adams, BSc

• Analyst with Datamonitor’s CNS & Pain business team providing in-depth market analysis and insight.
• Formerly Quality Control Microbiologist with Dabur Oncology UK.

James Wentworth, PhD

• James Wentworth is currently an Analyst in the Immunology & Inflammation team at Datamonitor;
• James has authored a number of reports covering inflammatory and musculoskeletal disorders, including osteoarthritis;
• James holds a PhD and (BSc Hons) from The University of Bristol. The focus of his PhD was on cell signalling mechanisms in human blood platelets.

Dates

2009 date to be communicated

Venue & Accommodation

This course takes place at the Sheraton Airport Hotel & Conference Center which is situated in front of the Brussels National Airport, literally at 2 minutes walking distance from the arrival hall.

Sheraton Brussels Airport Hotel
Brussels National Airport
1930 Zaventem
Belgium
Tel: +32 (0) 2 710 80 00
Fax: +32 (0) 2 710 80 80

We have secured preferential room rates at this five star hotel for our delegates. Registering three weeks or more prior to the course will secure your room at a preferential rate. Upon your registration, you will receive from C.E.L.forpharma a Sheraton Brussels Airport Hotel Accommodation Sheet for you to complete and return by fax. Do not hesitate to contact Marie Stricklesse, Programme Coordinator, if you need assistance in this matter (marie.stricklesse@celforpharma.com ; tel +32(0)27092241)

Testimonials

Since every therapy market seminar organized with Datamonitor is unique, we can only provide a selection of testimonials received from past participants at previous seminars.

"The "Commercial Outlook of Key CNS markets" was an interesting symposium that gave a very good overview. I still use the slides regularly look into the handout, certainly when I need something quickly and I don't have the time to dig into the lengthy reports."

Sonja Buyle, Associate Director New Product Commercialization CNS, UCB - Belgium

"The seminar provided valuable insight into the likely future trends in the respiratory market, supported by excellent analyses from Datamonitor."

Will Heath, Director of Business Strategy, Napp Pharmaceuticals - United Kingdom

"A very pertinent and important seminar to those involved in the development of drugs for respiratory diseases. The information on market trends was very precisely put over and left no doubts as to which future developments will be of priority. The expert opinions by Prof. Tim Higenbottam and the other speakers were well received and gave much food for thought. It was also a nice opportunity to interact with both presenters and participants and the informal atmosphere made it very easy to achieve this. Overall, top marks."

Ken Mugridge, Drug Development Manager, Curacyte Discovery - Germany

"Excellent insight was provided with the analyses from Datamonitor.
A must have for anyone in a strategically important function!"

Jurgen De Beule, (Former) Medical Manager, Sanofi-aventis - Belgium

“C.E.L.forpharma provided a very interesting mix of business and scientific considerations in oncology drug development, enhanced by the excellent content, presentation and knowledge of the speakers. I found it a very useful and stimulating day.”

Keith Jones, Senior Project Manager, Chugai Pharma Europe Ltd. - UK

(go to top)